|Bid||672.13 x 1100|
|Ask||819.87 x 800|
|Day's Range||749.67 - 768.87|
|52 Week Range||507.22 - 832.70|
|Beta (5Y Monthly)||0.89|
|PE Ratio (TTM)||5.62|
|Earnings Date||Oct 28, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||856.25|
Subscribe to Yahoo Finance Plus to view Fair Value for BIOLearn more
Recovery in Clinical Diagnostics arm and strong growth in Droplet Digital PCR platform are expected to have contributed to Bio-Rad's (BIO) Q3 results.
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.